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Recently heterozygous mutations in the active site of the
enzyme isocitrate dehydrogenase 1 (IDH1) were discov-
ered in glioblastomas [1]. In cohorts of glioma patients the
IDH1 mutation appeared to be a strong predictor of clin-
ical outcome, overruling histological malignancy grade [2].
IDH1 is an enzyme of the tricarboxylic acid (TCA) cycle
and is located in the cytosol, where it produces NADPH
by transforming isocitrate into α-ketoglutarate. Because
the mutant enzyme displays neomorphic activity through
NADPH-dependent transformation of α-ketoglutarate into
2-hydroxyglutarate (2HG), the tumorigenic role of the in-
creased levels of 2HG has become a target of speculation
[3]. IDH1 mutation alters the cellular metabolism and epi-
genetic phenotype influencing cellular proliferation. IDH1
mutation infers increased levels of D2HGDH leading to
the inhibition of DNA and histone demethylating en-
zymes, resulting in the glioma-CpG island phenotype [4].
Altered concentrations of pyruvate kinase M2 play also a
role in histone modifications which are associated with
the transcription of the proliferation-related cyclin D1 and
c-MYC [5]. In addition, IDH1 mutant cells show alter-
ations in glutamine, fatty acid and citrate synthesis path-
ways, which all may have their influence on cellular
proliferation [5].
The changes in IDH1 function affect the glucose metab-
olism, which may explain the different biological behav-
iour of tumors with and without the IDH1 mutation [6].
In order to detect these changes, we compared the expres-
sion levels of the genes participating in the TCA cycle and
in the anaerobic glycolysis in 33 IDH1 mutated samples (3
astrocytomas WHO grade II; 6 astrocytomas WHO grade
III; 4 glioblastomas; 9 oligodendrogliomas WHO grade II;
11 oligodendrogliomas WHO grade III) and in 39 IDH1
wild-type glioma samples (10 astrocytomas WHO grade
III; 26 glioblastomas; 1 oligodendroglioma WHO grade II;
2 oligodendroglioma WHO grade III) and in four samples
of normal brain (Table 1). We found expressional differ-
ences of 16/24 genes (Figure 1). The IDH1 mutated cells
seem to compensate for the low production of α-
ketoglutarate by overexpressing D2HGDH and L2HGDH
in the cytoplasm. They also overexpress GLUD1, which
converts glutamate to α-ketoglutarate inside the mito-
chondria. In addition, we found that IDH1 mutated cells
overexpress HIF1AN. The HIF1AN gene inhibits HIF1α.
Since HIF1α acts as an oxygen sensor that promotes
angiogenesis, the formation of dysfunctional tumor vascu-
lature is counteracted in IDH1 mutated cells. Further-
more, the IDH1 mutated cells overexpress the LDHB gene
while cells without IDH1 mutation overexpress the LDHA
gene. The present results illustrate that tumor cells with-
out IDH1 mutation switch their energy production from a
low rate of glycolysis followed by the TCA cycle to a high
rate of glycolysis followed by aerobic glycolysis (LDHA
up-regulation; Figure 1). The resulting lactate acid produc-
tion causes tissue acidosis known as the Warburg effect.
In invasive cancers, the pH of the extracellular space in-
creases the infiltrative potential of the tumor cells [7]. In
addition, normalization of the extracellular pH by alter-
ations of the enzymatic actions of LDHA and LDHB influ-
ences the progression of cancer cells [8,9]. It may well be
that glial tumor cells with IDH1 mutation tend to correct
their energy production through the TCA cycle by overex-
pressing LDHB (Figure 1). By doing so, they normalize the
tissue pH which offers yet another explanation for the less
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Table 1 Percentages of glioma types and grades
WHO grades IDH1 mutation IDH1 wild type
A II 4% 0%
A III 8% 14%
GBM 6% 36%
O II 13% 1%
O III 15% 3%
Legends: A II low-grade astrocytoma (WHO grade 2), A III anaplastic
astrocytoma (WHO grade 3), GBM glioblastoma (WHO grade 4), O II low-grade
oligodendroglioma (WHO grade 2), O III anaplastic oligodendroglioma
(WHO grade 3).
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aggressive biological behavior of the IDH1 mutated
gliomas.
We conclude that gliomas with IDH1 mutation
normalize their glucose metabolism, which appears to
result in a slower tumor progression. Depending on the
IDH1 status of the tumor, specific interference with the
glucose metabolism and aerobic glycolysis should there-
fore be considered for future therapeutic strategies.
Figure 1 Overview of alterations in glucose metabolism in the IDH1 mutated and IDH1 wild-type gliomas relative to glucose
metabolism in normal brain. The enzymes included in the analysis are shown in black. The bar diagrams show the averaged expressional levels
of genes that were significantly differently expressed in the IDH1 mutated gliomas (n = 33, blue bars on the left); IDH1 wild-type (n = 39, red bars
in the middle); and normal brain (n = 4, green bars on the right). Glycolysis leads to the production of pyruvate. In normal brain, pyruvate is
converted to acetyl-CoA, which enters the TCA cycle in the mitochondria. But in the IDH1 wild-type tumors, pyruvate is metabolized to lactate
(“the Warburg effect” in which the aerobic glycolysis serves as a quick energy source that results in tissue acidosis). To ensure the origin and
quality of the tissues, all tissues were assessed by a qualified pathologist before isolation. IDH1 status was checked using IHC and the standard
PCR test. Total RNA was isolated with the RNA-Bee (Campro, Veenendaal, The Netherlands). cDNA was prepared using the RevertAid H Minus First
Strand cDNA synthesis kit (Fermentas, St Leon-Rot, Germany). The resulting cDNA preparations were analysed by real-time PCR with SYPR green
master mix solution (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). PCRs were performed in a 25 μL reaction volume in an Applied
BioSystems 7900HT Fast Real-Time PCR system. Negative controls included minus RT and H2O-only samples, which were negative in all cases.
Expression of B2M, HPRT1 and PBGD was used as a reference to control sample loading and RNA quality. Differences in mRNA concentrations
were determined using the t-test, with P < 0.01 being considered statistically significant. All statistical tests were two-sided.
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